FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172189430> ?p ?o ?g. }

• W2172189430 endingPage "430" @default.
• W2172189430 startingPage "424" @default.
• W2172189430 abstract "Purpose To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Patients and Methods A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily. The primary end point was the major molecular response (MMR) rate at 12 months. Results At 12 months, differences in MMR and complete cytogenetic response (CCyR) rates were not statistically significant (MMR, 46% v 40%; P = .2035; CCyR, 70% v 66%; P = .3470). However, MMR occurred faster among patients randomly assigned to imatinib 800 mg/d, who had higher rates of MMR at 3 and 6 months compared with those in the imatinib 400-mg/d arm (P = .0035 by log-rank test). CCyR also occurred faster in the 800-mg/d arm (CCyR at 6 months, 57% v 45%; P = .0146). The most common adverse events were edema, gastrointestinal problems, and rash, and all were more common in patients in the 800-mg/d arm. Grades 3 to 4 hematologic toxicity also occurred more frequently in patients receiving imatinib 800 mg/d. Conclusion MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib." @default.
• W2172189430 created "2016-06-24" @default.
• W2172189430 creator A5002600757 @default.
• W2172189430 creator A5006302329 @default.
• W2172189430 creator A5011454613 @default.
• W2172189430 creator A5011922168 @default.
• W2172189430 creator A5015140142 @default.
• W2172189430 creator A5024952302 @default.
• W2172189430 creator A5034116258 @default.
• W2172189430 creator A5044224344 @default.
• W2172189430 creator A5045437866 @default.
• W2172189430 creator A5045566016 @default.
• W2172189430 creator A5046306389 @default.
• W2172189430 creator A5051359342 @default.
• W2172189430 creator A5057084037 @default.
• W2172189430 creator A5059502814 @default.
• W2172189430 creator A5068847117 @default.
• W2172189430 creator A5079181777 @default.
• W2172189430 creator A5084596816 @default.
• W2172189430 creator A5086618764 @default.
• W2172189430 creator A5089541690 @default.
• W2172189430 creator A5090435894 @default.
• W2172189430 date "2010-01-20" @default.
• W2172189430 modified "2023-10-02" @default.
• W2172189430 title "Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study" @default.
• W2172189430 cites W1548924510 @default.
• W2172189430 cites W1981809014 @default.
• W2172189430 cites W1986635169 @default.
• W2172189430 cites W1996081258 @default.
• W2172189430 cites W2016960626 @default.
• W2172189430 cites W2028959752 @default.
• W2172189430 cites W2057114258 @default.
• W2172189430 cites W2079517811 @default.
• W2172189430 cites W2079822043 @default.
• W2172189430 cites W2084734126 @default.
• W2172189430 cites W2106575058 @default.
• W2172189430 cites W2108472756 @default.
• W2172189430 cites W2120033838 @default.
• W2172189430 cites W2140111850 @default.
• W2172189430 cites W2148743957 @default.
• W2172189430 cites W2148831661 @default.
• W2172189430 cites W2149330162 @default.
• W2172189430 cites W2151968496 @default.
• W2172189430 cites W2166654361 @default.
• W2172189430 cites W2301293935 @default.
• W2172189430 cites W2521593057 @default.
• W2172189430 cites W2586556162 @default.
• W2172189430 doi "https://doi.org/10.1200/jco.2009.25.3724" @default.
• W2172189430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4979244" @default.
• W2172189430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20008622" @default.
• W2172189430 hasPublicationYear "2010" @default.
• W2172189430 type Work @default.
• W2172189430 sameAs 2172189430 @default.
• W2172189430 citedByCount "255" @default.
• W2172189430 countsByYear W21721894302012 @default.
• W2172189430 countsByYear W21721894302013 @default.
• W2172189430 countsByYear W21721894302014 @default.
• W2172189430 countsByYear W21721894302015 @default.
• W2172189430 countsByYear W21721894302016 @default.
• W2172189430 countsByYear W21721894302017 @default.
• W2172189430 countsByYear W21721894302018 @default.
• W2172189430 countsByYear W21721894302019 @default.
• W2172189430 countsByYear W21721894302020 @default.
• W2172189430 countsByYear W21721894302021 @default.
• W2172189430 countsByYear W21721894302022 @default.
• W2172189430 countsByYear W21721894302023 @default.
• W2172189430 crossrefType "journal-article" @default.
• W2172189430 hasAuthorship W2172189430A5002600757 @default.
• W2172189430 hasAuthorship W2172189430A5006302329 @default.
• W2172189430 hasAuthorship W2172189430A5011454613 @default.
• W2172189430 hasAuthorship W2172189430A5011922168 @default.
• W2172189430 hasAuthorship W2172189430A5015140142 @default.
• W2172189430 hasAuthorship W2172189430A5024952302 @default.
• W2172189430 hasAuthorship W2172189430A5034116258 @default.
• W2172189430 hasAuthorship W2172189430A5044224344 @default.
• W2172189430 hasAuthorship W2172189430A5045437866 @default.
• W2172189430 hasAuthorship W2172189430A5045566016 @default.
• W2172189430 hasAuthorship W2172189430A5046306389 @default.
• W2172189430 hasAuthorship W2172189430A5051359342 @default.
• W2172189430 hasAuthorship W2172189430A5057084037 @default.
• W2172189430 hasAuthorship W2172189430A5059502814 @default.
• W2172189430 hasAuthorship W2172189430A5068847117 @default.
• W2172189430 hasAuthorship W2172189430A5079181777 @default.
• W2172189430 hasAuthorship W2172189430A5084596816 @default.
• W2172189430 hasAuthorship W2172189430A5086618764 @default.
• W2172189430 hasAuthorship W2172189430A5089541690 @default.
• W2172189430 hasAuthorship W2172189430A5090435894 @default.
• W2172189430 hasBestOaLocation W21721894301 @default.
• W2172189430 hasConcept C126322002 @default.
• W2172189430 hasConcept C141071460 @default.
• W2172189430 hasConcept C197934379 @default.
• W2172189430 hasConcept C203092338 @default.
• W2172189430 hasConcept C2776960273 @default.
• W2172189430 hasConcept C2777482430 @default.
• W2172189430 hasConcept C2777583451 @default.
• W2172189430 hasConcept C2778461978 @default.
• W2172189430 hasConcept C2778729363 @default.
• W2172189430 hasConcept C29730261 @default.

• next